Accu-Reference Medical Lab Llc

CLIA Laboratory Citation Details

2
Total Citations
4
Total Deficiencyies
4
Unique D-Tags
CMS Certification Number 31D1041265
Address 1901 East Linden Avenue, Linden, NJ, 07036
City Linden
State NJ
Zip Code07036
Phone(908) 474-1004

Citation History (2 surveys)

Survey - June 11, 2021

Survey Type: Special

Survey Event ID: 0HSO11

Deficiency Tags: D2016 D2084 D6000

Summary:

Summary Statement of Deficiencies D2016 SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c) (a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS- approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history. This CONDITION is not met as evidenced by: Based on an office review of the CASPER reports 153 and 155 and Proficiency Testing (PT) provider reports, the laboratory failed to achieve a score of 80% or more for Diagnostic Immunology tests performed with the College of American Pathologists (CAP). The findings include: 1) The laboratory scored a 40% for Compliment C3 in event 2-20 with the CAP. 2) The laboratory scored a 60% for Compliment C3 in event 1-21 with the CAP. D2084 GENERAL IMMUNOLOGY CFR(s): 493.837(f) Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 2 -- Failure to achieve satisfactory performance for the same analyte or test in two consecutive testing events or two out of three consecutive testing events is unsuccessful performance. This STANDARD is not met as evidenced by: Based on an office review of the CASPER reports 153 and 155 and Proficiency Testing provider reports, the laboratory failed to achieve a score of 80% for General Immunology tests. The findings include: 1) The laboratory scored a 40% for Compliment C3 in event 2-20 with the College of American Pathologists (CAP). 2) The laboratory scored a 60% for Compliment C3 in event 1-21 with the CAP. D6000 MODERATE COMPLEXITY LABORATORY DIRECTOR CFR(s): 493.1403 The laboratory must have a director who meets the qualification requirements of 493. 1405 of this subpart and provides overall management and direction in accordance with 493.1407 of this subpart. This CONDITION is not met as evidenced by: Based on an office review of the CASPER reports 153 and 155 and Proficiency Testing (PT) provider reports, the laboratory director failed to provide appropriate direction to laboratory personnel to ensure that the PT surveys are performed satisfactorily and that the laboratory is compliance with the CLIA regulations. -- 2 of 2 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access

Survey - June 5, 2019

Survey Type: Standard

Survey Event ID: YJ9H12

Deficiency Tags: D5891

Summary:

Summary Statement of Deficiencies D5891 POSTANALYTIC SYSTEMS QUALITY ASSESSMENT CFR(s): 493.1299(a) The laboratory must establish and follow written policies and procedures for an ongoing mechanism to monitor, assess and, when indicated, correct problems identified in the postanalytic systems specified in 493.1291. This STANDARD is not met as evidenced by: Based on surveyor review of the Final Report (FR) and interview with the Laboratory Director (LD), the laboratory failed to identify problems on the FR for Drug Screen tests performed on the Beckman AU 580 from 1/2/19 to the date of the survey. The finding includes: 1. The Asterisk (*) on the FR referenced a comment which stated "all positive clinical drug screens must be considered presumptive positive and unconfirmed" but the results it referenced were not positive results. 2. The LD confirmed on 6/5/19 at 1:30 pm the the laboratory did not identify problems on the FR. Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 1 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access